MiniBooNE Results and Neutrino Schemes with 2 sterile Neutrinos: Possible Mass Orderings and Observables related to Neutrino Masses

The MiniBooNE and LSND experiments are compatible with each other when two sterile neutrinos are added to the three active ones. In this case there are eight possible mass orderings. In two of them both sterile neutrinos are heavier than the three active ones. In the next two scenarios both sterile neutrinos are lighter than the three active ones. The remaining four scenarios have one sterile neutrino heavier and another lighter than the three active ones. We analyze all scenarios with respect to their predictions for mass-related observables. These are the sum of neutrino masses as constrained by cosmological observations, the kinematic mass parameter as measurable in the KATRIN experiment, and the effective mass governing neutrinoless double beta decay. It is investigated how these non-oscillation probes can distinguish between the eight scenarios. Six of the eight possible mass orderings predict positive signals in the KATRIN and future neutrinoless double beta decay experiments. We also remark on scenarios with three sterile neutrinos. In addition we make some comments on the possibility of using decays of high energy astrophysical neutrinos to discriminate between the mass orderings in presence of two sterile neutrinos.Comment: 33 pages, 8 figures. Comments added, to appear in JHE

Demonstration of the temporal matter-wave Talbot effect for trapped matter waves

We demonstrate the temporal Talbot effect for trapped matter waves using ultracold atoms in an optical lattice. We investigate the phase evolution of an array of essentially non-interacting matter waves and observe matter-wave collapse and revival in the form of a Talbot interference pattern. By using long expansion times, we image momentum space with sub-recoil resolution, allowing us to observe fractional Talbot fringes up to 10th order.Comment: 17 pages, 7 figure

Kaon Production and Kaon to Pion Ratio in Au+Au Collisions at \snn=130 GeV

Mid-rapidity transverse mass spectra and multiplicity densities of charged and neutral kaons are reported for Au+Au collisions at \snn=130 GeV at RHIC. The spectra are exponential in transverse mass, with an inverse slope of about 280 MeV in central collisions. The multiplicity densities for these particles scale with the negative hadron pseudo-rapidity density. The charged kaon to pion ratios are $K^+/\pi^- = 0.161 \pm 0.002 {\rm (stat)} \pm 0.024 {\rm (syst)}$ and $K^-/\pi^- = 0.146 \pm 0.002 {\rm (stat)} \pm 0.022 {\rm (syst)}$ for the most central collisions. The $K^+/\pi^-$ ratio is lower than the same ratio observed at the SPS while the $K^-/\pi^-$ is higher than the SPS result. Both ratios are enhanced by about 50% relative to p+p and $\bar{\rm p}$+p collision data at similar energies.Comment: 6 pages, 3 figures, 1 tabl

The Ising Susceptibility Scaling Function

We have dramatically extended the zero field susceptibility series at both high and low temperature of the Ising model on the triangular and honeycomb lattices, and used these data and newly available further terms for the square lattice to calculate a number of terms in the scaling function expansion around both the ferromagnetic and, for the square and honeycomb lattices, the antiferromagnetic critical point.Comment: PDFLaTeX, 50 pages, 5 figures, zip file with series coefficients and background data in Maple format provided with the source files. Vs2: Added dedication and made several minor additions and corrections. Vs3: Minor corrections. Vs4: No change to eprint. Added essential square-lattice series input data (used in the calculation) that were removed from University of Melbourne's websit

Mid-rapidity anti-proton to proton ratio from Au+Au collisions at sNN=130 \sqrt{s_{NN}} = 130 GeV

We report results on the ratio of mid-rapidity anti-proton to proton yields in Au+Au collisions at \rts = 130 GeV per nucleon pair as measured by the STAR experiment at RHIC. Within the rapidity and transverse momentum range of $|y|<0.5$ and 0.4 $<p_t<$ 1.0 GeV/$c$, the ratio is essentially independent of either transverse momentum or rapidity, with an average of $0.65\pm 0.01_{\rm (stat.)} \pm 0.07_{\rm (syst.)}$ for minimum bias collisions. Within errors, no strong centrality dependence is observed. The results indicate that at this RHIC energy, although the $p$-\pb pair production becomes important at mid-rapidity, a significant excess of baryons over anti-baryons is still present.Comment: 5 pages, 3 figures, accepted by Phys. Rev. Let

Strange anti-particle to particle ratios at mid-rapidity in sqrt(s_NN)= 130 GeV Au+Au Collisions

Values of the ratios in the mid-rapidity yields of anti-Lambda/Lambda = 0.71 +/- 0.01(stat.) +/- 0.04(sys.), anti-Xi+/Xi- = 0.83 +/- 0.04(stat.) +/- 0.05 (sys.), anti-Omega+/Omega- = 0.95 +/- 0.15(stat) +/- 0.05(sys.) and K+/K- 1.092 +/- 0.023(combined) were obtained in central sqrt(s_NN) = 130 GeV Au+Au collisions using the STAR detector. The ratios indicate that a fraction of the net-baryon number from the initial system is present in the excess of hyperons over anti-hyperons at mid-rapidity. The trend in the progression of the baryon ratios, with increasing strange quark content, is similar to that observed in heavy-ion collisions at lower energies. The value of these ratios may be related to the charged kaon ratio in the framework of simple quark-counting and thermal models.Comment: 6 pages, 3 figures, revtex4, now accepted by Physics Letters B. All figures improved for clarity, fig. 2 now has kaon ratio separated by technique, fig. 3 now has additional other RHIC data points. Minor clarifications in text in response to referee comments. Updated ref

Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)

BACKGROUND: Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control. METHODS: Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75,000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. FINDINGS: 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995-99 and 2005-09 have generally been slight. For women diagnosed with ovarian cancer in 2005-09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18-23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease. INTERPRETATION: International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems